Quest Diagnostics (NYSE:DGX – Get Free Report) issued its quarterly earnings results on Tuesday. The medical research company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.04, Briefing.com reports. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.49%. The company had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.39 billion. During the same quarter last year, the business posted $2.30 EPS. Quest Diagnostics’s quarterly revenue was up 2.5% compared to the same quarter last year. Quest Diagnostics updated its FY 2024 guidance to 8.800-9.000 EPS and its FY24 guidance to $8.80-9.00 EPS.
Quest Diagnostics Trading Up 1.3 %
Shares of DGX traded up $1.88 during trading hours on Thursday, reaching $145.79. 448,667 shares of the company traded hands, compared to its average volume of 986,210. Quest Diagnostics has a 12 month low of $119.59 and a 12 month high of $150.59. The company has a quick ratio of 0.89, a current ratio of 0.97 and a debt-to-equity ratio of 0.59. The company’s fifty day moving average price is $141.06 and its two-hundred day moving average price is $134.39. The company has a market capitalization of $16.20 billion, a price-to-earnings ratio of 19.37, a price-to-earnings-growth ratio of 3.00 and a beta of 0.89.
Quest Diagnostics Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, July 22nd. Shareholders of record on Monday, July 8th were issued a $0.75 dividend. The ex-dividend date of this dividend was Monday, July 8th. This represents a $3.00 annualized dividend and a yield of 2.06%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 40.38%.
Insiders Place Their Bets
Analyst Upgrades and Downgrades
DGX has been the subject of several research reports. Mizuho increased their price target on Quest Diagnostics from $150.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. UBS Group lifted their target price on shares of Quest Diagnostics from $139.00 to $146.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Tuesday. Barclays raised their price target on Quest Diagnostics from $138.00 to $144.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. Finally, Robert W. Baird upped their price target on shares of Quest Diagnostics from $153.00 to $154.00 and gave the stock a “neutral” rating in a report on Wednesday. Nine analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $149.38.
Read Our Latest Report on Quest Diagnostics
About Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Featured Stories
- Five stocks we like better than Quest Diagnostics
- Why is the Ex-Dividend Date Significant to Investors?
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Canada Bond Market Holiday: How to Invest and Trade
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Investing in Travel Stocks Benefits
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.